Although neurological side effects secondary to PPIs are rare, several preclinical reports indicate that PPIs might increase A β levels, interact with tau protein, and affect the neuronal microenvironment through several mechanisms. PPIs are a widely indicated class of drugs for gastric acid-related disorders, although most older adult users are not treated for the correct indication. However, a recent case-control study reported decreased risk of dementia. Recent clinical studies have shown that proton pump inhibitors (PPIs) are associated with risk of dementia, including AD. Dementia and AD are chronic neurodegenerative conditions with a complex physiopathology involving both genetic and environmental factors. Further, AD is characterized by selective synaptic and neuronal degeneration, vascular dysfunction, and two histopathological features: extracellular amyloid plaques composed of amyloid beta peptide (A β) and neurofibrillary tangles formed by hyperphosphorylated tau protein. Alzheimer’s disease (AD) is the most common type of dementia, mainly encompassing cognitive decline in subjects aged ≥65 years.
0 kommentar(er)
